Oxurion Announces Amendment to Funding Program with Negma Group for EUR 6 Million in Funding
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Stay updated with breaking news from Beth Kurth. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Negma Group has converted 200 convertible bonds in Oxurion resulting in a EUR 500,000 capital increase. This is part of Negma Group's EUR 30 million Capital Commitment1 that will allow Oxurion to
24.08.2022 - Leuven, BELGIUM, Boston, MA, US – August 24, 2022 – Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, ...
Investegate announcements from Oxurion NV, Information on the Total Number of Voting Rights (Denominator) following Conversion of Negma Convertible Bonds and Partial Reimbursement of Kreos/Pontifax Convertible Bonds
Negma Group has converted 180 convertible bonds resulting in a EUR 450,000 capital increase and Kreos/Pontifax convertible bonds have been reimbursed in an amount of EUR 3 million Leuven, BELGIUM